← Leaderboards
John Chalmers Adair
University Of New Mexico
$3,712,368
Attributed
$3,712,368
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $710.5K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,712,368 · 6
By mechanism
P20$1,705,284 · 1
P30$1,408,095 · 1
M01$598,989 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of New Mexico
Same institution · by research overlap
- Cheryl L Willman$57,213,396
- Sally Melinda M Davis$19,128,261
- Philip George Zager$5,535,378
- Lisa Marie Cacari Stone$4,243,762
- Bonnie M Duran$5,295,339
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchAlzheimer&AposAlzheimer'S DiseaseBrain Disorder ChemotherapyHuman Therapy EvaluationClinical TrialsHuman SubjectPathologic ProcessInflammationImageLatinoEvaluationDementiaMagnetic Resonance ImagingCohortBiological MarkersClinical CenterCombination ChemotherapyChemopreventionCommunitiesCholinesterase InhibitorsDrug Screening /EvaluationLiquid SubstanceMixed Dementia
Grant awards (15)
Clinical Core$710,463
P30 · FY2025 · AG · contact PI
Clinical Core$697,632
P30 · FY2024 · AG · contact PI
Clinical Core$694,170
P20 · FY2022 · AG · contact PI
Clinical Core$511,314
P20 · FY2021 · AG · contact PI
Clinical Core$499,800
P20 · FY2020 · AG · contact PI
Evaluate the Efficacy and Safety of Vitamin E and Donepezil HCL (Aricept)$6,146
M01 · FY2004 · RR
Protease Func. in Degen. and Vascular Forms of Dementia$5,586
M01 · FY2004 · RR
N-ACETYLCYSTEINE IN DEMENTIA OF THE ALZHEIMER TYPE$282,412
M01 · FY2002 · RR
TRIAL OF VITAMIN E AND DONEPEZIL HCL TO DELAY CLINICAL PROGRESSION IN ALZHEIMER'S$0
M01 · FY2002 · RR
N-ACETYLCYSTEINE IN DEMENTIA OF THE ALZHEIMER TYPE$282,412
M01 · FY2001 · RR
TRIAL OF VITAMIN E AND DONEPEZIL HCL TO DELAY CLINICAL PROGRESSION IN ALZHEIMER'S$0
M01 · FY2001 · RR
N-ACETYLCYSTEINE IN DEMENTIA OF THE ALZHEIMER TYPE$22,433
M01 · FY2000 · RR
TRIAL OF VITAMIN E AND DONEPEZIL HCL TO DELAY CLINICAL PROGRESSION IN ALZHEIMER'S$0
M01 · FY2000 · RR
TRIAL OF VITAMIN E AND DONEPEZIL HCL TO DELAY CLINICAL PROGRESSION IN ALZHEIMER'S$0
M01 · FY2000 · RR
N-ACETYLCYSTEINE IN DEMENTIA OF THE ALZHEIMER TYPE$0
M01 · FY2000 · RR